Benitec Biopharma Inc.

NasdaqCM:BNTC Stock Report

Market Cap: US$266.8m

Benitec Biopharma Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Jerel Banks

Chief executive officer

US$2.8m

Total compensation

CEO salary percentage22.4%
CEO tenure6.6yrs
CEO ownershipn/a
Management average tenure6.6yrs
Board average tenure9.3yrs

Recent management updates

Most Shareholders Will Probably Find That The Compensation For Benitec Biopharma Inc.'s (NASDAQ:BNTC) CEO Is Reasonable

Nov 30
Most Shareholders Will Probably Find That The Compensation For Benitec Biopharma Inc.'s (NASDAQ:BNTC) CEO Is Reasonable

Recent updates

Companies Like Benitec Biopharma (NASDAQ:BNTC) Are In A Position To Invest In Growth

Oct 02
Companies Like Benitec Biopharma (NASDAQ:BNTC) Are In A Position To Invest In Growth

Most Shareholders Will Probably Find That The Compensation For Benitec Biopharma Inc.'s (NASDAQ:BNTC) CEO Is Reasonable

Nov 30
Most Shareholders Will Probably Find That The Compensation For Benitec Biopharma Inc.'s (NASDAQ:BNTC) CEO Is Reasonable

Benitec Biopharma prices of $18M securities offering

Sep 13

Benitec GAAP EPS of -$2.23, revenue of $0.07M

Sep 02

We're A Little Worried About Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Rate

Jan 13
We're A Little Worried About Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Rate

We Think Benitec Biopharma (NASDAQ:BNTC) Needs To Drive Business Growth Carefully

Sep 30
We Think Benitec Biopharma (NASDAQ:BNTC) Needs To Drive Business Growth Carefully

Will Benitec Biopharma (NASDAQ:BNTC) Spend Its Cash Wisely?

May 12
Will Benitec Biopharma (NASDAQ:BNTC) Spend Its Cash Wisely?

Benitec Bio secures $13M capital via equity offering

Apr 28

Can Benitec Biopharma (NASDAQ:BNTC) Afford To Invest In Growth?

Jan 27
Can Benitec Biopharma (NASDAQ:BNTC) Afford To Invest In Growth?

How Does Benitec Biopharma's (NASDAQ:BNTC) CEO Salary Compare to Peers?

Dec 02
How Does Benitec Biopharma's (NASDAQ:BNTC) CEO Salary Compare to Peers?

CEO Compensation Analysis

How has Jerel Banks's remuneration changed compared to Benitec Biopharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$21m

Jun 30 2024US$3mUS$628k

-US$22m

Mar 31 2024n/an/a

-US$22m

Dec 31 2023n/an/a

-US$22m

Sep 30 2023n/an/a

-US$21m

Jun 30 2023US$919kUS$540k

-US$20m

Mar 31 2023n/an/a

-US$20m

Dec 31 2022n/an/a

-US$19m

Sep 30 2022n/an/a

-US$18m

Jun 30 2022US$800kUS$506k

-US$18m

Mar 31 2022n/an/a

-US$17m

Dec 31 2021n/an/a

-US$18m

Sep 30 2021n/an/a

-US$16m

Jun 30 2021US$1mUS$440k

-US$14m

Mar 31 2021n/an/a

-US$13m

Dec 31 2020n/an/a

-US$11m

Sep 30 2020n/an/a

-US$10m

Jun 30 2020US$632kUS$400k

-US$8m

Mar 31 2020n/an/a

-US$7m

Dec 31 2019n/an/a

-US$6m

Sep 30 2019n/an/a

-US$2m

Jun 30 2019US$615kUS$400k

US$3m

Mar 31 2019n/an/a

US$2m

Dec 31 2018n/an/a

US$2m

Sep 30 2018n/an/a

-US$3m

Jun 30 2018US$91kn/a

-US$9m

Compensation vs Market: Jerel's total compensation ($USD2.80M) is above average for companies of similar size in the US market ($USD1.38M).

Compensation vs Earnings: Jerel's compensation has increased whilst the company is unprofitable.

CEO

Jerel Banks (49 yo)

6.6yrs

Tenure

US$2,798,977

Compensation

Dr. Jerel A. Banks, Ph D., M.D., has been the Chief Executive Officer of Benitec Biopharma Inc. since June 26, 2018. Dr. Banks has been the Executive Chairman of the Board at Benitec Biopharma Inc. since O...

Leadership Team

NamePositionTenureCompensationOwnership
Jerel Banks
Executive Chairman & CEO6.6yrsUS$2.80mno data
Megan Boston
Executive Director6.6yrsUS$1.28m0.11%
$ 297.9k
Sophie Mukadam
Chief Operating Officerno datano data0.026%
$ 69.1k
Michael Graham
Head of Discovery & Founding Scientist9.6yrsUS$238.78kno data
Claudia Kloth
Senior Vice President of Manufacturingno datano datano data

6.6yrs

Average Tenure

Experienced Management: BNTC's management team is seasoned and experienced (6.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jerel Banks
Executive Chairman & CEO8.3yrsUS$2.80mno data
Megan Boston
Executive Director8.4yrsUS$1.28m0.11%
$ 297.9k
J. Buchi
Independent Non-Executive Director11.8yrsUS$159.97k0.22%
$ 598.6k
Peter Francis
Independent Non-Executive Director18.9yrsUS$154.51k0.000080%
$ 213.4
Edward Smith
Independent Non-Executive Director4.8yrsUS$152.47k0%
$ 0
Kishan Mehta
Directorless than a yearno datano data
Geoffrey McCaughan
Member of Hepatology Clinical Advisory Board9.3yrsno datano data
Harry Janssen
Member of Hepatology Clinical Advisory Board9.3yrsno datano data
Keyur Patel
Member of Hepatology Clinical Advisory Board9.3yrsno datano data
George Dickson
Member of Scientific & Clinical Advisory Boardno datano datano data

9.3yrs

Average Tenure

52.5yo

Average Age

Experienced Board: BNTC's board of directors are considered experienced (9.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/07 23:24
End of Day Share Price 2025/01/07 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Benitec Biopharma Inc. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Debjit ChattopadhyayGuggenheim Securities, LLC
Raghuram SelvarajuH.C. Wainwright & Co.